Haleos Labs Limited (HALEOSLABS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002809,
    "name": "Haleos Labs Limi",
    "stock_name": "Haleos Labs Limi",
    "full_name": "Haleos Labs Limited",
    "name_url": "stocks-analysis/haleos-labs-limi",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,284.70",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "1,284.70",
    "mcapval": "388.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540679,
    "symbol": "HALEOSLABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE320X01016",
    "curr_date": "Feb 02",
    "curr_time": "",
    "bse_nse_vol": "267 ",
    "exc_status": "Active",
    "traded_date": "Feb 02, 2026",
    "traded_date_str": "2026 02 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/haleos-labs-limi-1002809-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Haleos Labs Limited Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-upgraded-to-hold-by-marketsmojo-amid-mixed-technical-and-financial-signals-3740757",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/HaleosLabsLimit_mojoScore_3740757.png",
        "date": "2025-12-02 08:58:04",
        "description": "Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation following a combination of recent financial results and technical market indicators. The company’s performance over various timeframes, alongside its valuation and technical trends, has prompted a nuanced reassessment of its investment profile."
      },
      {
        "title": "How has been the historical performance of Haleos Labs Limi?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-haleos-labs-limi-3739366",
        "imagepath": "",
        "date": "2025-12-01 23:32:30",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Examining the net sales figures, Haleos Labs Limi recorded ₹344.72 crores in the fiscal year ending March 2025, reflecting a recovery from a dip in the previous year when sales stood at ₹305.96 crores. The company’s revenue has oscillated over the years, peaking at ₹377.85 crores in March 2019 and experiencing a trough around ₹260.78 crores in March 2020. Despite these fluctuations, the firm has maintained a consistent operating profit margin, which improved to 13.07% in March 2025 from 10.17% in the prior year, signalling enhanced operational efficiency.</p>\n<p>Operating profit (PBDIT) excluding other income rose significantly to ₹45.04 crores in March 2025, up from ₹31.12 crores in March 2024. Including other income, operating profit reached..."
      },
      {
        "title": "Haleos Labs Limited Forms Golden Cross, Signalling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-forms-golden-cross-signalling-potential-bullish-breakout-3735949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HaleosLabsLimit_goldencross_3735949.png",
        "date": "2025-11-28 18:00:35",
        "description": "Haleos Labs Limited has recently experienced a significant technical event known as the Golden Cross, where its 50-day moving average has crossed above the 200-day moving average. This development is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company."
      },
      {
        "title": "SMS Lifesciences India: Analytical Review Highlights Shift in Market Assessment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sms-lifesciences-india-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3732676",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSLifesciences_mojoScore_3732676.png",
        "date": "2025-11-27 08:15:13",
        "description": "SMS Lifesciences India has experienced a notable revision in its market evaluation, reflecting changes across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This comprehensive review examines the factors influencing the current market perspective on the pharmaceutical and biotechnology company."
      },
      {
        "title": "Why is SMS Lifesciences falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sms-lifesciences-fallingrising-3722255",
        "imagepath": "",
        "date": "2025-11-22 01:23:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Recent Performance and Market Outperformance</strong></p>\n<p>SMS Lifesciences has demonstrated remarkable resilience and growth in recent periods. Over the past week, the stock surged by 8.92%, vastly outpacing the Sensex’s modest 0.79% gain. This trend extends over longer horizons, with the company delivering a 26.47% return in the last month compared to the Sensex’s 0.95%. Year-to-date, SMS Lifesciences has appreciated by 17.99%, nearly double the benchmark’s 9.08%. The stock’s one-year return of 36.80% further underscores its strong market performance, significantly outperforming the Sensex’s 10.47% and the BSE500 index over multiple time frames.</p>\n<p>Today's trading session highlighted the stock’s strength, opening with a gap up of 7.26% and reaching an intraday high of ₹1,525.2..."
      },
      {
        "title": "SMS Lifesciences India Reports Strong Growth Amid Mixed Long-Term Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sms-lifesciences-india-receives-stock-rating-upgrade-from-sell-to-hold-3706441",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSLifesciences_mojoScore_3706441.png",
        "date": "2025-11-17 08:14:40",
        "description": "SMS Lifesciences India has recently experienced an evaluation adjustment reflecting significant changes in its financial metrics. For the quarter ending September 2025, the company reported strong growth in key indicators, including Profit Before Tax and a favorable Debt-Equity Ratio, while also achieving notable earnings per share."
      },
      {
        "title": "How has been the historical performance of SMS Lifesciences?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sms-lifesciences-3703946",
        "imagepath": "",
        "date": "2025-11-15 00:19:40",
        "description": "Answer:\nThe historical performance of SMS Lifesciences shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nSMS Lifesciences reported net sales of 344.72 Cr in Mar'25, an increase from 305.96 Cr in Mar'24, but a decline from 349.74 Cr in Mar'22. The total operating income mirrored this trend, reaching 344.72 Cr in Mar'25. The company’s total expenditure, excluding depreciation, was 299.68 Cr in Mar'25, up from 274.84 Cr in Mar'24. Operating profit, excluding other income, improved to 45.04 Cr in Mar'25 from 31.12 Cr in the previous year, resulting in an operating profit margin of 13.07%. Profit before tax surged to 26.19 Cr in Mar'25, significantly higher than 9.85 Cr in Mar'24, while profit after tax also rose to 18.73 Cr from 6.33 Cr. The consolidated net profit for Mar'25 was 20.11 Cr, compared to 9.09 Cr in Mar'24. The earnings per share (EPS) increased to 66.59 in Mar'25 from ..."
      },
      {
        "title": "Why is SMS Lifesciences falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sms-lifesciences-fallingrising-3702854",
        "imagepath": "",
        "date": "2025-11-14 23:35:47",
        "description": "As of 14-Nov, SMS Lifesciences India Ltd is experiencing a price increase, currently at 1,311.00, reflecting a rise of 53.9 points or 4.29%. The stock has shown strong performance today, outperforming its sector by 3.92% and has been on a consecutive gain streak for the last six days, accumulating a total return of 13.02% during this period. It opened with a significant gain of 5.8% and reached an intraday high of Rs 1380, indicating strong buying interest. Additionally, the stock has demonstrated impressive returns over various periods, including a 1W return of 11.10% and a 1Y return of 19.22%. However, there has been a notable decline in investor participation, with delivery volume dropping by 53.94% against the 5-day average, which may raise concerns about sustainability.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has increased by 1.62% over the past week, SMS Lifesciences has ..."
      },
      {
        "title": "How has been the historical performance of SMS Lifesciences?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sms-lifesciences-3694271",
        "imagepath": "",
        "date": "2025-11-12 23:32:21",
        "description": "Answer:\nThe historical performance of SMS Lifesciences shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.\n\nBreakdown:\nSMS Lifesciences reported net sales of 344.72 Cr in March 2025, up from 305.96 Cr in March 2024, but down from 349.74 Cr in March 2022. The total operating income followed a similar trend, reaching 344.72 Cr in March 2025. The company's total expenditure, excluding depreciation, was 299.68 Cr in March 2025, which is an increase from 274.84 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 49.90 Cr, significantly higher than 34.95 Cr in March 2024, indicating improved operational efficiency. Profit before tax also saw a substantial rise to 26.19 Cr in March 2025 from 9.85 Cr in March 2024, while profit after tax increased to 18.73 Cr from 6.33 Cr in the previous year. The consolidated net profit for March 2025 was 20.11 Cr..."
      }
    ],
    "total": 417,
    "sid": "1002809",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/haleos-labs-limited-1002809"
  },
  "announcements": [
    {
      "caption": "Collaboration (HRV Global)",
      "datetime": "21-Jan-2026",
      "details": "Company has entered into Stategic Development collabration with HRV Global Life Sciences Private Limited and will make further disclosure as and when there is any material update on the same.",
      "source": "BSE"
    },
    {
      "caption": "Report (Special Window)",
      "datetime": "13-Jan-2026",
      "details": "Enclosed summary from December 1 2025 to January 6 2026.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Enclosed - RTA certificate.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Haleos Labs Limited has declared <strong>15%</strong> dividend, ex-date: 24 Sep 25",
          "dt": "2025-09-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Haleos Labs Limited Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:58:04

Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation following a combination of recent financial results and technical market indicators. The company’s performance over various timeframes, alongside its valuation and technical trends, has prompted a nuanced reassessment of its investment profile.

How has been the historical performance of Haleos Labs Limi?

2025-12-01 23:32:30

Revenue and Profitability Trends Examining the net sales figures, Haleos Labs Limi recorded ₹344.72 crores in the fiscal year ending March 2025, reflecting a recovery from a dip in the previous year when sales stood at ₹305.96 crores. The company’s revenue has oscillated over the years, peaking at ₹377.85 crores in March 2019 and experiencing a trough around ₹260.78 crores in March 2020. Despite these fluctuations, the firm has maintained a consistent operating profit margin, which improved to 13.07% in March 2025 from 10.17% in the prior year, signalling enhanced operational efficiency. Operating profit (PBDIT) excluding other income rose significantly to ₹45.04 crores in March 2025, up from ₹31.12 crores in March 2024. Including other income, operating profit reached...

Haleos Labs Limited Forms Golden Cross, Signalling Potential Bullish Breakout

2025-11-28 18:00:35

Haleos Labs Limited has recently experienced a significant technical event known as the Golden Cross, where its 50-day moving average has crossed above the 200-day moving average. This development is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company.

SMS Lifesciences India: Analytical Review Highlights Shift in Market Assessment

2025-11-27 08:15:13

SMS Lifesciences India has experienced a notable revision in its market evaluation, reflecting changes across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This comprehensive review examines the factors influencing the current market perspective on the pharmaceutical and biotechnology company.

Why is SMS Lifesciences falling/rising?

2025-11-22 01:23:50

Strong Recent Performance and Market Outperformance SMS Lifesciences has demonstrated remarkable resilience and growth in recent periods. Over the past week, the stock surged by 8.92%, vastly outpacing the Sensex’s modest 0.79% gain. This trend extends over longer horizons, with the company delivering a 26.47% return in the last month compared to the Sensex’s 0.95%. Year-to-date, SMS Lifesciences has appreciated by 17.99%, nearly double the benchmark’s 9.08%. The stock’s one-year return of 36.80% further underscores its strong market performance, significantly outperforming the Sensex’s 10.47% and the BSE500 index over multiple time frames. Today's trading session highlighted the stock’s strength, opening with a gap up of 7.26% and reaching an intraday high of ₹1,525.2...

SMS Lifesciences India Reports Strong Growth Amid Mixed Long-Term Performance Indicators

2025-11-17 08:14:40

SMS Lifesciences India has recently experienced an evaluation adjustment reflecting significant changes in its financial metrics. For the quarter ending September 2025, the company reported strong growth in key indicators, including Profit Before Tax and a favorable Debt-Equity Ratio, while also achieving notable earnings per share.

How has been the historical performance of SMS Lifesciences?

2025-11-15 00:19:40

Answer: The historical performance of SMS Lifesciences shows a fluctuating trend in key financial metrics over the years. Breakdown: SMS Lifesciences reported net sales of 344.72 Cr in Mar'25, an increase from 305.96 Cr in Mar'24, but a decline from 349.74 Cr in Mar'22. The total operating income mirrored this trend, reaching 344.72 Cr in Mar'25. The company’s total expenditure, excluding depreciation, was 299.68 Cr in Mar'25, up from 274.84 Cr in Mar'24. Operating profit, excluding other income, improved to 45.04 Cr in Mar'25 from 31.12 Cr in the previous year, resulting in an operating profit margin of 13.07%. Profit before tax surged to 26.19 Cr in Mar'25, significantly higher than 9.85 Cr in Mar'24, while profit after tax also rose to 18.73 Cr from 6.33 Cr. The consolidated net profit for Mar'25 was 20.11 Cr, compared to 9.09 Cr in Mar'24. The earnings per share (EPS) increased to 66.59 in Mar'25 from ...

Why is SMS Lifesciences falling/rising?

2025-11-14 23:35:47

As of 14-Nov, SMS Lifesciences India Ltd is experiencing a price increase, currently at 1,311.00, reflecting a rise of 53.9 points or 4.29%. The stock has shown strong performance today, outperforming its sector by 3.92% and has been on a consecutive gain streak for the last six days, accumulating a total return of 13.02% during this period. It opened with a significant gain of 5.8% and reached an intraday high of Rs 1380, indicating strong buying interest. Additionally, the stock has demonstrated impressive returns over various periods, including a 1W return of 11.10% and a 1Y return of 19.22%. However, there has been a notable decline in investor participation, with delivery volume dropping by 53.94% against the 5-day average, which may raise concerns about sustainability. Broader Market Context: In comparison to the benchmark Sensex, which has increased by 1.62% over the past week, SMS Lifesciences has ...

How has been the historical performance of SMS Lifesciences?

2025-11-12 23:32:21

Answer: The historical performance of SMS Lifesciences shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods. Breakdown: SMS Lifesciences reported net sales of 344.72 Cr in March 2025, up from 305.96 Cr in March 2024, but down from 349.74 Cr in March 2022. The total operating income followed a similar trend, reaching 344.72 Cr in March 2025. The company's total expenditure, excluding depreciation, was 299.68 Cr in March 2025, which is an increase from 274.84 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 49.90 Cr, significantly higher than 34.95 Cr in March 2024, indicating improved operational efficiency. Profit before tax also saw a substantial rise to 26.19 Cr in March 2025 from 9.85 Cr in March 2024, while profit after tax increased to 18.73 Cr from 6.33 Cr in the previous year. The consolidated net profit for March 2025 was 20.11 Cr...

View All News